SAS Output

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1558 228 15% 426 -1131 449 -1109
ERLYTX 76 42 55% 78 2 173 97
GI 476 117 25% 219 -257 283 -193
GU 450 424 94% 793 343 708 258
GYN 57 0 0% 0 -57 0 -57
LEUK 150 80 53% 149 0 156 6
LUNG 524 125 24% 233 -290 251 -273
LYMPH 172 165 96% 308 136 223 51
MELAN 55 103 187% 192 137 195 140
MMYEL 147 116 79% 217 70 179 32
OTHER 0 15   28 28 24 24
SXQOL 0 7   13 13 11 11
Total 3665 1422   2656 -1006 2652 -1013

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 37 22 59% 41 4 54 17
CCD 0 434   812 812 1234 1234
GU 0 2   3 3 17 17
LEUK 69 0 0% 0 -69 0 -69
LUNG 43 535 1244% 1001 958 1085 1042
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 8   14 14 8 8
PEOLC 0 14   26 26 31 31
PREV 0 13   24 24 40 40
SURV 0 45   84 84 99 99
SXQOL 878 252 29% 471 -406 364 -514
Total 1172 1325   2476 1305 2932 1760

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1595 250 16% 467 -1127 503 -1092
CCD 0 434   812 812 1234 1234
ERLYTX 76 42 55% 78 2 173 97
GI 476 117 25% 219 -257 283 -193
GU 450 426 95% 797 347 725 275
GYN 57 0 0% 0 -57 0 -57
LEUK 219 80 37% 149 -69 156 -63
LUNG 567 660 116% 1235 668 1336 769
LYMPH 225 165 73% 308 83 223 -2
MELAN 55 103 187% 192 137 195 140
MMYEL 239 116 49% 217 -21 179 -60
OTHER 0 23   43 43 32 32
PEOLC 0 14   26 26 31 31
PREV 0 13   24 24 40 40
SURV 0 45   84 84 99 99
SXQOL 878 259 29% 484 -393 375 -503
Total 4837 2747   5135 302 5584 747

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1012 136 13% 254 -757 262 -750
ERLYTX 76 29 38% 54 -21 111 35
GI 418 72 17% 134 -283 158 -260
GU 375 313 83% 585 210 527 152
GYN 57 0 0% 0 -57 0 -57
LEUK 122 78 64% 146 24 148 26
LUNG 441 73 17% 136 -304 168 -273
LYMPH 129 91 71% 170 41 125 -4
MELAN 55 78 142% 146 91 133 78
MMYEL 85 76 89% 142 57 120 35
OTHER 0 15   28 28 24 24
SXQOL 0 7   13 13 11 11
Total 2770 968   1808 -958 1787 -983

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 10 22 220% 41 31 54 44
CCD 0 394   737 737 1051 1051
GU 0 2   3 3 17 17
LEUK 69 0 0% 0 -69 0 -69
LUNG 30 284 947% 531 501 601 571
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 6   11 11 6 6
PEOLC 0 10   18 18 22 22
PREV 0 9   16 16 28 28
SURV 0 33   61 61 77 77
SXQOL 740 238 32% 445 -294 348 -392
Total 994 998   1863 870 2204 1210

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 1022 158 15% 295 -726 316 -706
CCD 0 394   737 737 1051 1051
ERLYTX 76 29 38% 54 -21 111 35
GI 418 72 17% 134 -283 158 -260
GU 375 315 84% 589 214 544 169
GYN 57 0 0% 0 -57 0 -57
LEUK 191 78 41% 146 -45 148 -43
LUNG 471 357 76% 668 197 769 298
LYMPH 182 91 50% 170 -11 125 -57
MELAN 55 78 142% 146 91 133 78
MMYEL 177 76 43% 142 -34 120 -57
OTHER 0 21   39 39 30 30
PEOLC 0 10   18 18 22 22
PREV 0 9   16 16 28 28
SURV 0 33   61 61 77 77
SXQOL 740 245 33% 458 -281 359 -381
Total 3764 1966   3673 -85 3991 227

13-JUL-2020 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

53% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010		 2020
Accrual
to date		 Percentage
of Base
Accrual		 Projected
2020
Accrual		 Projected
Increase
<Decrease>
from Base		 Accrual
Last
12 Months		 12 Month
Increase
<Decrease>
from Base
BREAST 65 220 338% 411 346 443 378
CCD 0 107   200 200 571 571
GI 81 11 14% 20 -60 24 -57
GU 215 412 192% 771 556 652 437
LEUK 0 38   71 71 76 76
LUNG 53 5 9% 9 -43 7 -46
LYMPH 7 115 1643% 215 208 149 142
MELAN 0 4   7 7 9 9
MMYEL 0 6   11 11 6 6
OTHER 0 6   11 11 11 11
PEOLC 0 14   26 26 31 31
PREV 0 13   24 24 40 40
SURV 0 45   84 84 99 99
SXQOL 878 259 29% 484 -393 375 -503
Total 1299 1255   2344 1048 2493 1194

13-JUL-2020 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center		 Open
Date		 Months
Open		 Total
Regs		 Accrual
Goal		 Monthly
Accrual
Rate		 Date of
Expected Closure or
Temporary Closure
  BIOL SLA01 LA Gastric Ca, Immune Checkpoint Expression SWOG 02APR2019:00:00:00 15 0 400 0.0 > 15 Yrs
BREAST II EA1181 BRST, HER2-pCR, Preop THP and Postop HP ECOG-ACRIN 11FEB2020:00:00:00   2   0.4  
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 22 48 300 2.8 Nov-2027
  III A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   305   3.5  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   167   3.5  
    B51 Breast, Regional Nodal XRT NRG 22AUG2013:00:00:00   42   0.5  
    EA1131 Brst, TNBC, Post-op Chemo vs Obs ECOG-ACRIN 20AUG2014:00:00:00   25   0.5  
    MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG 30MAY2018:00:00:00   2   0.2  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   84   0.3  
    NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG 12MAR2019:00:00:00   2   0.2  
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 43 826 1000 26.7 Jan-2021
CCD II EAQ171CD Smoke Free Support Study 2.0 ECOG-ACRIN 11APR2019:00:00:00   1   0.0  
  III EA1151 CCD, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   1174   48.2  
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 23 81 1320 5.3 > 15 Yrs
  OTHER A231602C Blood Cancer, Assess Financial Difficulty ALLIANCE 15MAR2019:00:00:00   4   0.7  
    ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   54   0.5  
    EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer ECOG-ACRIN 17MAY2018:00:00:00   44   0.8  
    NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   77   1.8  
  PILOT S1916 Pain, Mets, Opioid Digital Medicine Pilot SWOG 15OCT2019:00:00:00 8 2 60 0.3 Jan-2035
ERLYTX II S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 42 739 818 5.5 Sep-2021
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   174   0.8  
GI II EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   5   0.0  
    EA2165 Anal, Stg II-III, Nivolumab after CMT ECOG-ACRIN 13APR2018:00:00:00   23   1.7  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 33 33 130 0.8 Mar-2030
    S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect SWOG 16DEC2019:00:00:00 6 1 94 0.2 > 15 Yrs
  II-III NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG 16DEC2019:00:00:00   1   0.2  
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   28   1.0  
    A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo ALLIANCE 18JUL2018:00:00:00   8   0.3  
    A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 ALLIANCE 30SEP2019:00:00:00   4   0.7  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   14   0.5  
    S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel SWOG 03DEC2018:00:00:00 19 276 441 12.2 Aug-2021
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   5   0.5  
    A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) ALLIANCE 12APR2019:00:00:00   10   0.7  
    A031803 Blad, NMIBC, Gemcitabine + MK-3475 ALLIANCE 06JAN2020:00:00:00   3   0.5  
    EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) ECOG-ACRIN 08FEB2018:00:00:00   24   0.2  
    EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi ECOG-ACRIN 09JUL2018:00:00:00   23   0.3  
    NRGGU006 PROS, post-RP PSA, SRT +/- ADT w/Apalutamide NRG 27APR2018:00:00:00   4   0.2  
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   3   0.0  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   6   0.0  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   67   1.7  
    A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo ALLIANCE 09MAY2019:00:00:00   20   2.3  
    EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT ECOG-ACRIN 08SEP2017:00:00:00   6   0.3  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACRIN 02FEB2017:00:00:00   102   4.7  
    NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG 16NOV2017:00:00:00   2   0.2  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 41 761 969 36.8 Dec-2020
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 21 215 1273 10.8 Aug-2028
    S1806 Blad, MIBC, ChemoRT +/- Atezolizumab SWOG 19APR2019:00:00:00 14 75 475 7.2 Feb-2025
LEUK I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00 66 55 58 0.7 Nov-2020
  II EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs ECOG-ACRIN 03OCT2018:00:00:00   1   0.2  
    S1712 CML, Chronic Phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 23 30 84 2.0 Sep-2022
  II-III A041701 AML, Age 60+, Conv Chemo +/- Uproleselan ALLIANCE 16JAN2019:00:00:00   13   1.2  
    S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00   78 1670   Oct-2018 Temp Close
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   13   1.2  
    A041702 CLL, Stg I-IV, IO with IM versus IVO ALLIANCE 04JAN2019:00:00:00   26   1.0  
    EA9161 CLL, untreated, IOV vs IO in younger pts ECOG-ACRIN 03JAN2019:00:00:00   106   6.0  
LUNG II S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 23 7 66 0.8 May-2026
    S1800A Non-Match: Ramu + Pembro vs SoC SWOG 17MAY2019:00:00:00 13 118 144 8.5 Oct-2020
    S1900A LOH and/or BRCA: Rucaparib SWOG 28JAN2019:00:00:00 17 64 88 4.0 Dec-2020
    S1900B RET Fusion: Selpercatinib (LOXO-292) SWOG 10FEB2020:00:00:00 5 2 124 0.4 > 15 Yrs
    S1900C STK11: Talazoparib + Avelumab SWOG 16JAN2020:00:00:00 5 17 44 2.9 Apr-2021
    S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib SWOG 15JUN2020:10:13:46 0 0 94    
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
    NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG 07APR2017:00:00:00   1   0.0  
    NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG 28MAY2019:00:00:00   1   0.0  
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   64   0.7  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   15   0.2  
    EA5163 NSCLC, Immunotherapy +/- 2nd line therapy ECOG-ACRIN 28FEB2019:00:00:00   19   0.8  
    S1827 SCLC, MRI Surveillance +/- PCI SWOG 10JAN2020:00:00:00 6 5 668 0.8 > 15 Yrs
    S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo SWOG 25MAR2020:00:00:00 3 0 480 0.0 > 15 Yrs
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   813   4.7  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 17 1369   81.3  
  PILOT S1933 NSCLC, Stg II-III, RT + Atezo SWOG 15JUN2020:10:15:53 0 0 47    
LYMPH I-II E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin ECOG-ACRIN 24JAN2014:00:00:00   8   0.3  
  II EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A ECOG-ACRIN 03OCT2019:00:00:00   8   1.2  
    S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00 35 48 150 1.5 Feb-2026
  II-III A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax ALLIANCE 07AUG2019:00:00:00   19   2.8  
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   8   0.2  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   42   2.0  
    S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD SWOG 19JUL2019:00:00:00 11 149 987 18.8 Mar-2024
MELAN II S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 44 39 56 0.7 Aug-2022
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 33 43 64 2.3 Mar-2021
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 35 93 94 3.8 Jul-2020
    S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab SWOG 06DEC2018:00:00:00 19 127 556 7.5 Apr-2025
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACRIN 15DEC2015:00:00:00   49   0.7  
    EA6174 Merkel, Adjuvant Pembrolizumab vs Observation ECOG-ACRIN 23JUL2018:00:00:00   11   1.3  
MMYEL I/II A061202 MM, Poma/Dexa/Ixaz vs Poma/Dexa ALLIANCE 07FEB2014:00:00:00   2   0.2  
  II EAA173 MYEL, SMM, Rd +/- Daratumumab ECOG-ACRIN 30APR2019:00:00:00   6   1.0  
  III S1803 MM, Maintenance, Len vs Len/Dara SWOG 27JUN2019:00:00:00 12 158 1100 17.0 Feb-2025
OTHER II A091802 cSCC, Advanced Avelumab +/- Cetuximab ALLIANCE 17MAY2019:00:00:00   1   0.2  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   18   0.2  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.0  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo ECOG-ACRIN 20JUN2019:00:00:00   7   1.0  
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   4   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   7   0.0  
    NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG 12DEC2017:00:00:00   4   0.3  
    NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG 10JUL2019:00:00:00   3   0.3  
  III AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo COG 30JUL2018:00:00:00   1   0.0  
    G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   9   0.2  
    NRGBN003 Mening, Grd II, Observation vs Irradiation NRG 14JUN2017:00:00:00   3   0.2  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
  OTHER A151804 irAEs, National Biorepository to Adv Studies ALLIANCE 31JAN2020:00:00:00   1   0.2  
    NCICOVID NCI COVID-19 in Cancer Patients Study NCI 21MAY2020:00:00:00   7      
PEOLC PILOT S1820 Rectal, Diet modification to manage GI sx SWOG 09DEC2019:00:00:00 7 9 94 1.5 Mar-2025
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    A211601 Breast, Stg II-III, Aspirin ALLIANCE 01AUG2018:00:00:00   2   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 88 278 491 1.8 Mar-2030
  OTHER S1823 GCT, Obs. Cohort, miRNA371 SWOG 01JUN2020:13:00:37 1 0 956    
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACRIN 30SEP2015:00:00:00   23   0.0  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 33 197 817 5.8 May-2029
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   20   0.0  
    EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACRIN 16AUG2017:00:00:00   42   1.2  
SXQOL II A171601 Breast, ER+ HER2- Met, Palboc + Letroz/Fulves ALLIANCE 15AUG2018:00:00:00   2   0.3  
  III A221505 Brst, Hypofractionated Post Mast Rad ALLIANCE 01FEB2018:00:00:00   19   0.8  
    A221602 CINV in HEC patients, Olanza +/- Fosapre ALLIANCE 15OCT2018:00:00:00   13   1.8  
    A221702 BREAST, SLN/ALND +/- ARM ALLIANCE 31MAY2019:00:00:00   15   2.5  
    S1600 Bladder,Radical Cystectomy Outcomes Nutrition SWOG 21FEB2019:00:00:00   15 200   Oct-2019 Temp Close
    S1614 HBV in Ca Pts, TAF vs SOC SWOG 21FEB2019:00:00:00 16 2 444 0.3 > 15 Yrs
  OTHER S1714 CIPN Risk Prediction Cohort Study, Taxanes SWOG 01MAR2019:00:00:00 16 339 1050 33.7 Apr-2022
  PILOT A221504 NSCL, Advanced, placebo vs naloxegol ALLIANCE 13OCT2017:00:00:00   6   0.3  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

13-JUL-2020 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp		 Stat
Center		 Study NCIPROTO CA
Cntrl
Study		 Temp
Close
BIOL   N   SLA01 LA Gastric Ca, Immune Checkpoint Expression   N  
OTHER CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y  
    Y ECOG-ACRIN EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer EAQ162CD Y  
    Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
    Y ALLIANCE A231602C Blood Cancer, Assess Financial Difficulty A231602CD N  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ALLIANCE A151804 irAEs, National Biorepository to Adv Studies A151804 N  
    Y NCI NCICOVID NCI COVID-19 in Cancer Patients Study NCICOVID N  
  PREV Y SWOG S1823 GCT, Obs. Cohort, miRNA371 S1823 Y  
  SURV Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
    Y ECOG-ACRIN EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
  SXQOL N   S1714 CIPN Risk Prediction Cohort Study, Taxanes   Y  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N  
  LYMPH Y ECOG-ACRIN E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin E4412 N  
II BREAST Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 N  
    Y ECOG-ACRIN EA1181 BRST, HER2-pCR, Preop THP and Postop HP EA1181 N  
  CCD Y ECOG-ACRIN EAQ171CD Smoke Free Support Study 2.0 EAQ171CD Y  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y SWOG S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect S1922 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y ECOG-ACRIN EA2165 Anal, Stg II-III, Nivolumab after CMT EA2165 N  
  GU Y ECOG-ACRIN EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) EA8153 N  
    Y ECOG-ACRIN EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi EA8171 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
    Y NRG NRGGU006 PROS, post-RP PSA, SRT +/- ADT w/Apalutamide NRG-GU006 N  
    Y ALLIANCE A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) A031702 N  
    Y ALLIANCE A031803 Blad, NMIBC, Gemcitabine + MK-3475 A031803 N  
  LEUK Y SWOG S1712 CML, Chronic Phase, TKI +/- Ruxolitinib S1712 N  
    Y ECOG-ACRIN EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs EA9171 N  
  LUNG Y SWOG S1900C STK11: Talazoparib + Avelumab S1900C N  
    Y SWOG S1900A LOH and/or BRCA: Rucaparib S1900A N  
    Y SWOG S1900B RET Fusion: Selpercatinib (LOXO-292) S1900B N  
    Y SWOG S1800A Non-Match: Ramu + Pembro vs SoC S1800A N  
    Y SWOG S1929 ESCLC, SLFN11+, Atezolizumab ± Talazoparib S1929 N  
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N  
    Y ECOG-ACRIN EA4181 MCL, Randomization BR/CR v BR/CR-A v BR-A EA4181 N  
  MELAN Y SWOG S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab S1801 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y ECOG-ACRIN EAA173 MYEL, SMM, Rd +/- Daratumumab EAA173 Y  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
    Y ALLIANCE A091802 cSCC, Advanced Avelumab +/- Cetuximab A091802 N  
  SXQOL Y ALLIANCE A171601 Breast, ER+ HER2- Met, Palboc + Letroz/Fulves A171601 Y  
PILOT CCD N   S1916 Pain, Mets, Opioid Digital Medicine Pilot   Y  
  LUNG Y SWOG S1933 NSCLC, Stg II-III, RT + Atezo S1933 N  
  PEOLC Y SWOG S1820 Rectal, Diet modification to manage GI sx S1820 Y  
  SXQOL Y ALLIANCE A221504 NSCL, Advanced, placebo vs naloxegol A221504 Y  
II-III GI Y NRG NRGGI005 COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy NRG-GI005 N  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N Y
    Y ALLIANCE A041701 AML, Age 60+, Conv Chemo +/- Uproleselan A041701 N  
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
    Y NRG NRGLU005 LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo NRG-LU005 Y  
    Y NRG NRGLU002 LUNG, Limited Met NSCLC, MST vs LCT + MST NRG-LU002 Y  
  LYMPH Y ALLIANCE A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax A051701 N  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGHN004 HN, Adv, RT+Durvalumab vs RT+Cetuximab NRG-HN004 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG NRGHN005 HN, early stg P16-pos, randomize de-intensifi NRG-HN005 Y  
    Y ECOG-ACRIN EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo EA3161 N  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
III BREAST     EA1131 Brst, TNBC, Post-op Chemo vs Obs   N  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y NRG NRGBR004 BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo NRG-BR004 Y  
    Y CCTG MA39 BREAST, Node-Pos, Reg RT vs No Reg RT CCTG MA.39 Y  
  CCD Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ECOG-ACRIN EA1151 CCD, Tomosynthesis Mammographic Screening EA1151 N  
  GI Y SWOG S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel S1815 N  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
    Y ALLIANCE A021602 PANC, Adv PNET Blinded Cabozantinib v Placebo A021602 Y  
    Y ALLIANCE A021703 COLON, Adv/Met, Chemo + Std v High dose V-D3 A021703 N  
  GU Y SWOG S1806 Blad, MIBC, ChemoRT +/- Atezolizumab S1806 Y  
    Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT NRG-GU005 Y  
    Y ALLIANCE A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo A031704 Y  
    Y ECOG-ACRIN EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT EA8134 Y  
    Y ECOG-ACRIN EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN EA9161 CLL, untreated, IOV vs IO in younger pts EA9161 Y  
    Y ALLIANCE A041702 CLL, Stg I-IV, IO with IM versus IVO A041702 N  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
  LUNG Y SWOG S1827 SCLC, MRI Surveillance +/- PCI S1827 Y  
    Y SWOG S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo S1914 N  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
    Y ECOG-ACRIN EA5163 NSCLC, Immunotherapy +/- 2nd line therapy EA5163 N  
  LYMPH Y SWOG S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD S1826 Y  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
    Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
  MELAN Y ECOG-ACRIN EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
    Y ECOG-ACRIN EA6174 Merkel, Adjuvant Pembrolizumab vs Observation EA6174 N  
  MMYEL Y SWOG S1803 MM, Maintenance, Len vs Len/Dara S1803 N  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG NRGBN003 Mening, Grd II, Observation vs Irradiation NRG-BN003 Y  
    Y COG AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo AGCT1532 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
    Y ALLIANCE A211601 Breast, Stg II-III, Aspirin A211601 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACRIN E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y SWOG S1600 Bladder,Radical Cystectomy Outcomes Nutrition S1600 Y Y
    Y SWOG S1614 HBV in Ca Pts, TAF vs SOC S1614 Y  
    Y ALLIANCE A221702 BREAST, SLN/ALND +/- ARM A221702 Y  
    Y ALLIANCE A221602 CINV in HEC patients, Olanza +/- Fosapre A221602 Y  
    Y ALLIANCE A221505 Brst, Hypofractionated Post Mast Rad A221505 Y  
I/II MMYEL Y ALLIANCE A061202 MM, Poma/Dexa/Ixaz vs Poma/Dexa A061202 N  

13-JUL-2020 6:10

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number		 Study Accrual
Goal		 Open
Stat/Date		 Months
Open		 Accrual
as of
01Jan02		 Current Accrual Proj.
Annual
Accr.
Rate		 EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 491 Y-03/01/13 88 278 278 22 Mar-2030 > 15 Yrs
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 43 826 826 320 Jan-2021 4.2
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 33 197 197 70 May-2029 11.7
S1600 S1600 Bladder,Radical Cystectomy Outcomes Nutrition (SXQOL) 200 T-02/21/19 16 15 15 0 > 15 Yrs > 15 Yrs
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 41 761 761 442 Dec-2020 3.9
S1612 S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics (LEUK) 1670 T-12/22/17 30 78 78 0 > 15 Yrs > 15 Yrs
S1614 S1614 HBV in Ca Pts, TAF vs SOC (SXQOL) 444 Y-02/21/19 16 2 2 4 > 15 Yrs > 15 Yrs
S1703 S1703 Met Breast, STM-monitoring v Usual Care (CCD) 1320 Y-07/16/18 23 81 81 64 > 15 Yrs > 15 Yrs
S1802 S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU) 1273 Y-09/17/18 21 215 215 130 Aug-2028 9.9
S1803 S1803 MM, Maintenance, Len vs Len/Dara (MMYEL) 1100 Y-06/27/19 12 158 158 204 Feb-2025 5.6
S1806 S1806 Blad, MIBC, ChemoRT +/- Atezolizumab (GU) 475 Y-04/19/19 14 75 75 86 Feb-2025 5.8
S1815 S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel (GI) 441 Y-12/03/18 19 276 276 146 Aug-2021 2.7
S1826 S1826 HD, Adv, Age 12+, N+AVD vs BV+AVD (LYMPH) 987 Y-07/19/19 11 149 149 226 Mar-2024 4.7
S1827 S1827 SCLC, MRI Surveillance +/- PCI (LUNG) 668 Y-01/10/20 6 5 5 10 > 15 Yrs > 15 Yrs
S1914 S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG) 480 Y-03/25/20 3 0 0 0 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.